医药电商

Search documents
佐力药业涨2.05%,成交额8322.21万元,主力资金净流入1198.85万元
Xin Lang Cai Jing· 2025-09-24 02:29
佐力药业所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:基因测序、医药电商、中 药、生物医药、创新药等。 9月24日,佐力药业盘中上涨2.05%,截至10:16,报17.92元/股,成交8322.21万元,换手率0.78%,总市 值125.69亿元。 资金流向方面,主力资金净流入1198.85万元,特大单买入0.00元,占比0.00%,卖出106.94万元,占比 1.28%;大单买入2414.17万元,占比29.01%,卖出1108.38万元,占比13.32%。 佐力药业今年以来股价涨21.34%,近5个交易日跌0.78%,近20日跌6.42%,近60日涨2.40%。 资料显示,浙江佐力药业股份有限公司位于浙江省德清县阜溪街道志远北路388号,成立日期2000年1月 28日,上市日期2011年2月22日,公司主营业务涉及药用真菌乌灵系列和百令片产品、中药饮片及中药 配方颗粒的研发、生产与销售。主营业务收入构成为:乌灵系列56.07%,中药饮片系列21.85%,其他 产品10.11%,百令系列7.08%,中药配方颗粒4.62%,其他(补充)0.26%。 责任编辑:小浪快报 截至6月30日,佐力药业股 ...
康惠制药涨2.01%,成交额825.62万元,主力资金净流入29.59万元
Xin Lang Cai Jing· 2025-09-24 02:12
Core Insights - Kanghui Pharmaceutical's stock price increased by 2.01% on September 24, reaching 22.33 CNY per share, with a total market capitalization of 2.23 billion CNY [1] - The company has experienced a year-to-date stock price increase of 55.50%, but has seen a decline of 5.66% over the last five trading days [2] Financial Performance - For the first half of 2025, Kanghui Pharmaceutical reported a revenue of 248 million CNY, a year-on-year decrease of 6.83%, and a net profit attributable to shareholders of -40.20 million CNY, a significant decline of 362.01% [2] - The company has not distributed any dividends in the last three years, with a total payout of 54.23 million CNY since its A-share listing [3] Shareholder Information - As of June 30, the number of shareholders increased by 37.26% to 12,000, while the average number of tradable shares per shareholder decreased by 27.14% to 8,326 shares [2]
珍宝岛跌2.09%,成交额1773.24万元,主力资金净流入196.45万元
Xin Lang Cai Jing· 2025-09-23 02:32
Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on October 28, 1996, and listed on April 24, 2015. The company focuses on the research, production, and sales of high-end traditional Chinese medicine formulations, with a diverse range of dosage forms and products [2]. Financial Performance - For the first half of 2025, Zhenbaodao reported operating revenue of 714 million yuan, a year-on-year decrease of 57.05%. The net profit attributable to the parent company was -78.29 million yuan, reflecting a year-on-year decline of 119.90% [2]. - Since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Zhenbaodao's stock price decreased by 2.09%, trading at 11.27 yuan per share, with a total market capitalization of 10.605 billion yuan. The stock has seen a decline of 1.57% year-to-date, 8.74% over the last five trading days, 11.05% over the last 20 days, and 3.18% over the last 60 days [1][2]. - The trading volume on September 23 was 17.7324 million yuan, with a turnover rate of 0.17%. The net inflow of main funds was 1.9645 million yuan, with significant buying activity from large orders [1]. Business Segmentation - The main business revenue composition includes: 84.82% from the sale of proprietary Chinese medicines, 7.13% from purchased medicinal materials, 5.11% from purchased pharmaceuticals, 2.51% from other sources, 0.35% from rental income, and 0.07% from interest income [2]. - Zhenbaodao is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]. Shareholder Information - As of July 18, the number of shareholders for Zhenbaodao was 21,500, an increase of 2.34% from the previous period. The average circulating shares per person decreased by 2.29% to 43,744 shares [2].
何氏眼科跌2.02%,成交额1599.53万元,主力资金净流入87.21万元
Xin Lang Cai Jing· 2025-09-23 02:27
Core Viewpoint - He Eye Hospital's stock price has experienced fluctuations, with a year-to-date increase of 2.14% but a significant decline in recent trading periods, indicating potential volatility in investor sentiment [2]. Company Overview - He Eye Hospital Group, established on October 15, 2009, and listed on March 22, 2022, is located in Shenyang, Liaoning Province. The company specializes in providing ophthalmic specialty diagnosis and treatment services [2]. - The revenue composition of He Eye Hospital includes: Vision services (30.24%), Refractive surgery correction services (24.16%), Non-surgical treatments (20.02%), Cataract diagnosis and treatment services (13.68%), Vitreoretinal diagnosis and treatment services (8.09%), Other ophthalmic diagnosis and treatment services (3.20%), and Other business income (0.61%) [2]. Financial Performance - As of June 30, 2025, He Eye Hospital reported a revenue of 560 million yuan, a year-on-year decrease of 4.22%. However, the net profit attributable to shareholders was 44.32 million yuan, reflecting a significant year-on-year increase of 84.19% [2]. - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for He Eye Hospital was 10,800, an increase of 15.03% from the previous period. The average circulating shares per person decreased by 13.07% to 7,684 shares [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B fund held 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3].
汤臣倍健跌2.01%,成交额7288.73万元,主力资金净流出1415.80万元
Xin Lang Cai Jing· 2025-09-23 02:24
Company Overview - Tongrentang's stock price decreased by 2.01% on September 23, trading at 11.70 CNY per share with a market capitalization of 19.793 billion CNY [1] - The company specializes in the research, production, and sales of dietary nutritional supplements, with revenue composition as follows: Others 38.02%, Capsules 27.84%, Tablets 20.38%, Powders 13.76% [1] Financial Performance - For the first half of 2025, Tongrentang reported a revenue of 3.532 billion CNY, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million CNY, down 17.34% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 8.321 billion CNY, with 2.429 billion CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.96% to 71,200, while the average circulating shares per person increased by 5.22% to 15,869 shares [2] - Major shareholders include E Fund's ChiNext ETF, holding 24.5972 million shares, a decrease of 648,400 shares from the previous period [3]
健之佳跌2.05%,成交额1205.59万元,主力资金净流出62.31万元
Xin Lang Cai Jing· 2025-09-23 02:17
9月23日,健之佳盘中下跌2.05%,截至09:59,报20.59元/股,成交1205.59万元,换手率0.38%,总市值 31.82亿元。 截至6月30日,健之佳股东户数1.51万,较上期减少12.99%;人均流通股10236股,较上期增加26.21%。 2025年1月-6月,健之佳实现营业收入44.57亿元,同比减少0.64%;归母净利润7237.82万元,同比增长 15.11%。 资料显示,健之佳医药连锁集团股份有限公司位于云南省昆明市盘龙区联盟街道旗营街10号,成立日期 2004年9月27日,上市日期2020年12月1日,公司主营业务涉及药品、保健食品、个人护理品、家庭健康 用品、便利食品、日用消耗品等健康产品的连锁零售业务,并提供相关专业服务。主营业务收入构成 为:处方、非处方合计(中西成药)72.60%,其中:非处方药39.64%,其中:处方药32.96%,医疗器械 7.44%,其他(补充)5.52%,生活便利品5.05%,保健食品4.84%,中药材3.28%,个人护理品1.18%,体 检服务0.09%。 (000727)位居第五大流通股东,持股710.00万股,相比上期减少29.48万股。广发创 ...
振东制药跌2.03%,成交额3888.94万元,主力资金净流出679.12万元
Xin Lang Cai Jing· 2025-09-23 01:48
Core Viewpoint - The stock of Zhendong Pharmaceutical has experienced fluctuations, with a year-to-date increase of 67.82%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - On September 23, Zhendong Pharmaceutical's stock fell by 2.03%, trading at 7.25 CNY per share, with a total market capitalization of 7.289 billion CNY [1]. - The stock has seen a net outflow of 6.7912 million CNY in principal funds, with significant selling pressure in the last trading session [1]. - Year-to-date, the stock has increased by 67.82%, but it has declined by 3.85% over the last five trading days and 23.28% over the last 20 days [1]. Group 2: Company Overview - Zhendong Pharmaceutical, established on November 15, 1995, and listed on January 7, 2011, is located in Changzhi, Shanxi Province [2]. - The company specializes in the research, production, and sales of generic and innovative drugs across various therapeutic areas, including oncology and urology [2]. - The revenue composition includes 54.82% from traditional Chinese medicine, 43.10% from chemical drugs, and 1.98% from other sources [2]. Group 3: Financial Performance - For the first half of 2025, Zhendong Pharmaceutical reported a revenue of 1.457 billion CNY, a year-on-year decrease of 3.30%, and a net profit attributable to shareholders of 7.9313 million CNY, down 74.13% year-on-year [2]. - The company has distributed a total of 3.372 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. - As of June 30, 2025, the number of shareholders decreased by 5.04% to 46,100, while the average circulating shares per person increased by 5.31% to 21,777 shares [2].
【公告全知道】固态电池+人形机器人+锂电池+低空经济+特斯拉!公司固态电池已在部分车型试装车及量产
财联社· 2025-09-22 15:25
Group 1 - The article highlights significant announcements in the stock market, including "suspensions and resumption of trading, shareholding changes, investment wins, acquisitions, performance reports, unlocks, and high transfers" [1] - A company has successfully tested solid-state batteries in some vehicle models and has begun mass production, with these batteries also being utilized in humanoid robot products [1] - Another company in the semiconductor sector is expected to see its net profit double year-on-year in the first three quarters, with significant holdings from the National Big Fund [1] - A pharmaceutical e-commerce company has received approval for a new indication for its innovative drug, Puyouke, which is based on traditional Chinese medicine [1]
华人健康跌0.54%,成交额4335.82万元,今日主力净流入-200.51万
Xin Lang Cai Jing· 2025-09-22 07:27
Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is experiencing a decline in stock price and trading volume, indicating potential challenges in the market despite its growth in revenue and profit [1][4]. Group 1: Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. Its main business involves pharmaceutical agency, retail, and terminal procurement [7]. - The company's revenue composition is primarily from traditional Chinese and Western medicine, accounting for 97.60%, with other products making up 2.40% [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Group 2: Financial Performance - For the first half of 2023, the company achieved a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% year-on-year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - The company is actively expanding its presence on major e-commerce platforms, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me [2]. - The company is focusing on the integration of artificial intelligence in its operations, enhancing service efficiency and customer experience through AI medical consultations and customer service [2][3]. - As of June 30, 2023, the company is developing 22 research drugs, focusing on traditional Chinese medicine and high-end generic drugs [3]. Group 4: Stock Performance and Trading Activity - On September 22, 2023, the company's stock price fell by 0.54%, with a trading volume of 43.3582 million yuan and a turnover rate of 2.24%, resulting in a total market capitalization of 5.184 billion yuan [1]. - The stock has seen a net outflow of 2.0051 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5]. - The average trading cost of the stock is 14.27 yuan, with the current price approaching a support level of 12.67 yuan, suggesting potential volatility if this support is breached [6].
太极集团跌2.03%,成交额1.60亿元,主力资金净流出2098.45万元
Xin Lang Zheng Quan· 2025-09-22 06:32
Core Viewpoint - Tai Chi Group's stock has experienced a decline in both price and trading volume, reflecting a challenging financial performance in recent periods [1][2]. Group 1: Stock Performance - On September 22, Tai Chi Group's stock price fell by 2.03%, reaching 21.23 CNY per share, with a trading volume of 1.60 billion CNY and a market capitalization of 118.23 billion CNY [1]. - Year-to-date, the stock price has decreased by 14.12%, with a 1.80% drop over the last five trading days, a 10.46% decline over the last 20 days, and a slight decrease of 0.38% over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Tai Chi Group reported a revenue of 5.658 billion CNY, representing a year-on-year decrease of 27.63%, and a net profit attributable to shareholders of 139 million CNY, down 71.94% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 483 million CNY, with 167 million CNY distributed over the last three years [3]. Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 8.15% to 54,100, while the average circulating shares per person increased by 8.87% to 10,296 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.2524 million shares, a decrease of 880,600 shares, while the Southern CSI 1000 ETF is a new entrant with 3.6013 million shares [3].